Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data sought on prostate cancer combo therapy

NCT ID NCT06380738

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study watches how men with a certain advanced prostate cancer (mCRPC) do when taking the drugs olaparib and abiraterone in everyday medical practice. It will track about 250 patients for up to 2 years to see how long they stay on treatment and what happens next. The goal is to learn more about real-world results, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

111 people

The number who actually took part.

Started

Feb 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of patients with a confirmed mCRPC diagnosis that has initiated the combination of olaparib and abiraterone through routine clinical practice at participating sites in Germany.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent; * 18 years of age and above; * Documented histopathology or cytopathology of PCa, adenocarcinoma; * Confirmed as mCRPC; * Initiated olaparib + abiraterone after site activation Exclusion Criteria: * Patients participating in a clinical trial with an investigational prostate cancer treatment within 30 days prior to olaparib initiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic castration resistant prostate cancer

Contacts and locations

Locations

  • Research Site

    Aschaffenburg, Germany

  • Research Site

    Augsburg, Germany

  • Research Site

    Bergisch Gladbach, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Cologne, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Duisburg, Germany

  • Research Site

    Eisenach, Germany

  • Research Site

    Eisleben Lutherstadt, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Greifswald, Germany

  • Research Site

    Halle, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Heinsberg, Germany

  • Research Site

    Herzogenaurach, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Lichtenfels, Germany

  • Research Site

    Lübeck, Germany

  • Research Site

    Lüneburg, Germany

  • Research Site

    Magdeburg, Germany

  • Research Site

    Marburg, Germany

  • Research Site

    Mülheim, Germany

  • Research Site

    Münster, Germany

  • Research Site

    Nuremberg, Germany

  • Research Site

    Rüsselsheim am Main, Germany

  • Research Site

    Saalfeld, Germany

  • Research Site

    Speyer, Germany

  • Research Site

    Trier, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Westerstede, Germany

  • Research Site

    Wetzlar, Germany

  • Research Site

    Winnenden, Germany

  • Research Site

    Wuppertal, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.